Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the vaccine protects vulnerable infants

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can vary from causing mild, cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”

The pregnancy vaccine operates by activating the mother’s body’s defences to produce protective antibodies, which are then passed to the foetus through the placenta. This maternal immunity provides newborns with instant defence from the moment of birth, precisely when they are most vulnerable to RSV. The latest research demonstrates that protection reaches nearly 85 per cent when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver meaningful protection, with evidence suggesting that a fortnight’s interval is adequate to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine at the recommended time, whilst noting that protection can still occur even if administered later in the third trimester.

• Nearly 85% protection when immunised four weeks before birth
• Antibodies from the mother transferred through the placenta protect newborns from day one
• Protection possible with two-week gap before premature birth
• Vaccination in the third trimester still offers significant infant protection

Strong evidence from current research

The efficacy of the pregnancy RSV vaccine has been demonstrated through a comprehensive study undertaken in England, examining data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90 per cent of all births during that six-month period, providing comprehensive and reliable information of the vaccine’s real-world impact. The study’s conclusions have been endorsed by the UK Health Security Agency as showing “excellent protection” for newborns during their most vulnerable early months. The breadth of this investigation offers healthcare professionals and parents-to-be with trust in the vaccine’s proven efficacy across different groups and contexts.

The results present a compelling picture of the vaccine’s ability to protect. More than 4,500 babies were hospitalised with RSV during the study period, with the great majority being infants whose mothers had not received the vaccination. This clear distinction highlights the vaccine’s vital importance in protecting against serious illness in newborns. The decrease in hospital admissions surpassing 80 per cent represents a significant public health achievement, possibly preventing thousands of infants from experiencing the alarming and potentially severe symptoms connected with severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.

Study design and parameters

The research examined birth and hospital admission records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish direct comparisons of RSV infection rates and hospitalisations. The substantial sample size and comprehensive nature of the data gathering ensured that findings were statistically robust and representative of the broader population, rather than individual cases or limited subgroups.

The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at different timepoints before delivery. This allowed researchers to establish the minimum time required between vaccination and birth for optimal protection, as well as to determine whether protection stayed significant with shorter intervals. The methodology measured real-world outcomes rather than laboratory-based settings, providing practical evidence of how the vaccine works when delivered across different clinical contexts and patient circumstances throughout the final three months of pregnancy.

Comprehending RSV and the dangers

Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.

The infection causes inflammation deep within the lungs and airways, making it perilously hard for affected infants to feed and breathe properly. Parents frequently observe their babies visibly struggling, their chests heaving as they try to pull adequate oxygen into their damaged lungs. Whilst most infants recover with palliative treatment, a limited though important proportion perish from RSV complications annually, making vaccination as prevention a vital health service objective for safeguarding the youngest and most at-risk people in our communities.

• RSV causes lung inflammation, causing severe breathing difficulties in babies
• Approximately half of infants catch the infection during their first few months alive
• Symptoms vary between minor cold-like symptoms to life-threatening chest infections needing hospital treatment
• Over 20,000 UK babies require serious hospital care for RSV each year
• Few infants die from RSV related complications annually in the UK

Uptake rates and specialist advice

Since the RSV vaccine programme began in 2024, health officials have stressed the value of pregnant women getting their jab at the optimal time for greatest protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has stressed that timing is crucial for ensuring newborns benefit from the most robust immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery provides approximately 85% protection, experts advise women to receive their vaccine as soon as feasible from 28 weeks of pregnancy forward to maximise the antibodies transferred to their babies via the placenta.

The messaging from health authorities remains clear: pregnant women ought to prioritise getting vaccinated during their final three months, even if circumstances mean they cannot receive the jab at the best timing. Dr Watson has reassured expectant mothers that protection is still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those delivering slightly early. This flexible approach acknowledges the realities of pregnancy and childbirth whilst ensuring strong safeguarding for at-risk infants during their earliest and most vulnerable period when RSV represents the highest danger of serious illness.

Regional disparities in immunisation

Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have varied across different regions and NHS trusts. Some areas have achieved greater immunisation rates among eligible pregnant women, whilst others continue working to increase awareness and access to the jab. These regional differences reflect variations in healthcare infrastructure, communication strategies, and community involvement initiatives, though the overall statistics shows robust and reliable protection regardless of geographical location.

• NHS trusts launching varied communication campaigns to connect with pregnant women
• Geographic variations in immunisation take-up across England necessitate strategic intervention
• Community health services modifying schemes to align with specific population needs

Practical implications and parent viewpoints

The vaccine’s remarkable effectiveness provides concrete gains for families throughout the United Kingdom. With over 20,000 babies hospitalised annually due to RSV before the launch of this protective measure, the 80% reduction in admissions equates to thousands of infants shielded from critical disease. Parents no longer face the upsetting situation of seeing their babies labour to breathe or struggle to eat, symptoms that characterise serious RSV disease. The vaccine has substantially transformed the terrain of neonatal breathing health, providing expectant mothers a proactive tool to protect their most vulnerable children during those critical early months.

For families like that of Malachi, whose serious RSV infection led to devastating brain damage, the vaccine’s introduction carries deep personal significance. His mother’s support of the jab emphasises the life-altering consequences that preventable illness can inflict on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to expectant mothers in their final trimester, changing what was once an inevitable seasonal threat into a manageable health risk.